真实世界数据在随机对照试验中的力量与潜力:多方利益相关者智库会议纪要
2024年5月杜克临床研究所召开智库会议,汇集学术界、产业界、医疗系统、监管机构和患者倡导组织专家,探讨将真实世界数据(RWD)整合到随机对照试验(RCT)中的方法学、监管和操作挑战。会议聚焦患者识别与结局评估优化、RWD用于安全性评估以及RWD支持监管审批的RCT三大领域,并提出五项可操作建议。
要点
- RWD可简化入选标准、通过人工智能增强招募、提供实用终点评估疗效。
- 需标准化RWD来源以确保一致性并提高跨医疗系统互操作性。
- 应制定监管框架明确RWD在临床试验中可接受的用途。
核心结论
- RWD有潜力提升RCT效率,但需多方协作解决数据不一致、隐私和基础设施限制等挑战。
- 实施五项建议策略对充分发挥RWD在临床研究中的潜力至关重要。
研究设计与样本
- 2024年5月在杜克临床研究所召开的多方利益相关者智库会议,汇集学术界、产业界、医疗系统、监管机构和患者倡导组织专家。
- 讨论聚焦三个关键领域:优化患者识别与结局评估、利用RWD进行安全性评估、在支持监管审批的RCT中使用RWD。
主要发现
- RWD可简化入选标准、通过人工智能增强招募、提供评估治疗效应的实用终点。
- 智库会议强调需要跨利益相关者合作以应对数据不一致、隐私担忧和基础设施限制等挑战。
关键数值与推荐
- 建议标准化RWD来源以确保一致性并提高跨医疗系统互操作性。
- 建议制定监管框架定义RWD在临床试验中可接受的用途。
- 建议通过稳健验证方法和实时监测提升数据质量。
- 建议投资人工智能驱动的患者识别工具以简化招募。
- 建议促进多方利益相关者合作以对齐期望并分享最佳实践。
临床怎么用
- 在RCT设计中考虑整合RWD以优化患者识别和招募。
- 利用RWD进行安全性评估和提供实用终点。
- 遵循标准化和监管框架确保RWD质量与合规性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Randomized controlled trials (RCTs) remain the gold standard for evaluating medical interventions, but they often face challenges related to patient recruitment, cost, and efficiency. Real-world data (RWD) has emerged as a valuable tool to enhance trial design, improve patient identification, and support regulatory decision-making. However, integrating RWD into RCTs presents methodological, regulatory, and operational challenges. To address these issues, a think tank was convened in May 2024 at the Duke Clinical Research Institute, bringing together experts from academia, industry, healthcare systems, regulatory agencies, and patient advocacy groups. Discussions focused on three key areas: optimizing patient identification and outcome assessment, leveraging RWD for safety assessments, and using RWD in RCTs supporting regulatory approval. RWD has the potential to simplify eligibility criteria, enhance recruitment through artificial intelligence, and provide practical endpoints for evaluating treatment effects. The think tank underscored the need for collaboration across stakeholders to address challenges, such as data inconsistencies, privacy concerns, and infrastructure limitations. The event concluded with actionable recommendations, including the following: (1) standardizing RWD sources to ensure consistency and improve interoperability across healthcare systems, (2) developing regulatory frameworks that define acceptable use cases for RWD in clinical trials, (3) enhancing data quality through robust validation methodologies and real-time monitoring, (4) investing in artificial intelligence-driven patient identification tools to streamline recruitment, and (5) fostering multi-stakeholder collaboration to align expectations and share best practices. Moving forward, implementing these strategies will be critical to fully harness the potential of RWD in clinical research and improve trial efficiency.
引用
- Nouhravesh N, Jackman JG, Hernandez AF, et al. The power, potential of real-world data in randomized controlled trials: proceedings from a multistakeholder think tank. Trials. 2026. PMID: 41963997. doi:10.1186/s13063-026-09680-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。